Wedbush Reiterates an 'Outperform' on Sunesis Pharmaceuticals (SNSS); Increased Confidence After Board Recommendation
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Price: $5.32 --0%
Rating Summary:
5 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 6
Rating Summary:
5 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 6
Join SI Premium – FREE
Wedbush reiterates an 'Outperform' on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) price target of $7.00 (from $4.00).
Analyst, David M. Nierengarten, said, "SNSS announced that the Data Safety Monitoring Board met and recommended a one-time, 50% (225 patient) sample size increase for the VALOR Phase III trial of vosaroxin in relapsed/refractory AML patients...With the increased trial enrollment, we now expect final data for the VALOR trial in mid-2014, with FDA/EMA approvals in early 2015, assuming priority review, as relapsed/refractory AML remains a significant unmet medical need with median patient survival currently at less than 6 months with standard treatments."
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $2.64 yesterday.
Analyst, David M. Nierengarten, said, "SNSS announced that the Data Safety Monitoring Board met and recommended a one-time, 50% (225 patient) sample size increase for the VALOR Phase III trial of vosaroxin in relapsed/refractory AML patients...With the increased trial enrollment, we now expect final data for the VALOR trial in mid-2014, with FDA/EMA approvals in early 2015, assuming priority review, as relapsed/refractory AML remains a significant unmet medical need with median patient survival currently at less than 6 months with standard treatments."
For an analyst ratings summary and ratings history on Sunesis Pharmaceuticals Inc. click here. For more ratings news on Sunesis Pharmaceuticals Inc. click here.
Shares of Sunesis Pharmaceuticals Inc. closed at $2.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
- ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
- Nomura/Instinet Downgrades Indraprastha Gas Ltd. (IGL:IN) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
